



Citation for published version:

Ainsworth, B, Hardman, D & Thomas, M 2019, 'The importance of differentiating behavioural and psychological treatment effects from placebo in respiratory interventions', *European Respiratory Journal*, vol. 53, no. 4, 1900156. <https://doi.org/10.1183/13993003.00156-2019>

DOI:

[10.1183/13993003.00156-2019](https://doi.org/10.1183/13993003.00156-2019)

Publication date:

2019

Document Version

Peer reviewed version

[Link to publication](#)

This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the *European Respiratory Journal*, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1
2
3 **The importance of differentiating behavioural and psychological treatment**
4 **effects from placebo in respiratory interventions.**
5

6
7 **B Ainsworth**

8 Department of Psychology, Faculty of Humanities & Social Sciences, University of Bath.
9

10
11 **D Hardman**

12 Primary Care and Population Sciences, Faculty of Medicine, University of Southampton.
13

14
15 **M Thomas**

16 Primary Care and Population Sciences, Faculty of Medicine, University of Southampton.
17

18 @ERSpublications: Well-designed non-pharmacological interventions can harness
19 treatment responses seen in the placebo arm.
20
21
22

23 We read with interest the piece by Pattinson and Wanigaseraka [1], discussing the
24 clinical implications of the recent trial by Currow et al. [2], which demonstrated parity
25 between sertraline and placebo for improving breathlessness intensity. In particular,
26 Pattinson and Wanigaseraka noted that differential response expectations can
27 potentially confound outcomes between otherwise balanced intervention vs. placebo-
28 controlled groups. Such expectations have clinical implications: the management of
29 response expectations should be examined and potentially harnessed to improve
30 treatment outcomes for patients with chronic breathlessness, as suggested by
31 Similowski and Serresse [3].
32
33

34 In his excellent paper, Turner [4] reiterated that a placebo-controlled trial (PCT)
35 compares a particular component of a treatment (often primarily pharmacological)
36 while attempting to keep all other therapeutically-relevant components identical.
37 Ideally, such an approach precludes bias and is the gold-standard to develop evidence-
38 based medical treatments. However, chronic breathlessness (amongst other complex
39 long-term conditions) is increasingly recognised as dysfunction across multiple
40 interconnected systems. As such it requires holistic treatment that, alongside
41 physiological factors, addresses social, psychological, neurocognitive and behavioural
42 aspects of disease. Therefore, it must be acknowledged that although PCTs are designed
43 to examine one specific treatment component, multiple components will impact patient
44 outcomes – and these components may be present in both the treatment and placebo
45 group.
46
47
48
49

50 This issue is particularly relevant in respiratory research, in which studies have
51 consistently demonstrated very limited associations between objective physiological
52 impairment and the subjective perceptions of breathlessness severity [5,6]. Thus,
53 treatment benefits may impact patients through a diverse and complex interacting set
54 of mechanisms (such as neurocognitive predispositions towards subjective symptom
55 severity, as suggested by Ongaro and Kaptchuk [7]) which Pattinson and Wanigaseraka
56 rightly note may not be balanced between PCT trial arms. Pertinently, we do not wish to
57 devalue ‘traditional’ RCTs. However, evidence from such trials should be considered
58 alongside other types of research methods, such as ‘pragmatic’ research that more
59
60

1
2
3 closely reflects routine clinical care and 'additively' evaluates the incorporation of a new
4 treatment to a patients' existing care, carefully monitoring all aspects of the new
5 treatment (e.g. interaction with healthcare, subsequent self-management) in order to
6 understand the likely mechanisms by which treatment benefits are conferred.
7

8
9 Many medical professionals think of a 'placebo' as an inert pill but, as Turner noted, a
10 comparison with 'placebo' in a trial is merely a comparison of one group with another –
11 and the 'placebo pill' is merely a symbolic object involved in this process. This process
12 definition is in line with modern accounts of clinical placebos focussed on context,
13 meaning and embodiment. We also agree with Pattinson and Wanigaseraka's point that
14 'placebo' is often used disparagingly to refer to treatments that do not work; such a
15 position risks overlooking the benefits that are conferred independently to identified
16 physiological improvements. This is particularly relevant for non-pharmacological
17 treatments such as breathing retraining exercises, mindfulness-based treatments or
18 cognitive behavioural therapy, which are increasingly used as effective patient
19 treatments in respiratory disease but demonstrate no measurable effect on
20 physiological outcomes. By defining placebos as 'inert' substances we are in danger of
21 classifying such complementary treatments as ineffective, when in fact they may be
22 cost-effective adjunct treatments that offer tangible patient benefits.
23
24
25

26
27 We welcome the call for 'open-label' placebo research. However, a considered and
28 cautious approach should be taken, insofar as such treatment may merely demonstrate
29 the presence of broad psychological and behavioural treatment effects without
30 determining which of these can be targeted (and therefore impacted by well-designed
31 non-pharmacological interventions). Moreover, as Currow[8] notes (supported by
32 modern contextual accounts of the placebo phenomenon[9]), although the results of
33 small-scale open-label placebo trials may reflect genuine therapeutic benefit, they may
34 also just be an artefact of the experimental situation – meaning it is unclear how such a
35 treatment reponse can be harnessed.
36
37

38
39 These effects of open-label placebos are not caused by the 'inert' pill itself, but by the
40 construction and exploitation of a whole treatment process. Given that many existing
41 non-pharmacological interventions can be conceived of as already established whole
42 treatment processes (without the negative connotations of placebos) we advocate that
43 the best way to therapeutically employ beneficial treatment responses may be to
44 conduct careful research on these non-pharmacological interventions.
45
46

47 **References**

- 48
49 1. Pattinson K, Wanigasekera V. Sertraline or placebo in chronic breathlessness?
50 Lessons from placebo research. *Eur Respir J* 2019; 0: 1802225.
- 51 2. Currow DC, Ekström M, Louw S, et al. Sertraline in symptomatic chronic
52 breathlessness: a double blind, randomised trial. *Eur Respir J* 2019; 53: 1801270.
- 53 3. Similowski T, Serresse L. Lessons from negative dyspnoea studies: arguments for
54 the multidimensional evaluation of multidirectional therapeutic approaches. *Eur*
55 *Respir J* 2019; 53: 1802471
- 56 4. Turner, A. (2012). 'Placebos' and the logic of placebo comparison. *Biology &*
57 *Philosophy*, 27(3), 419-432. DOI: 10.1007/s10539-011-9289-8.
58
59
60